Metoclopramida Labesfal (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide works by blocking dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, which enhances gastric motility. It also antagonizes peripheral 5‑HT3 receptors, contributing to its antiemetic effect, and modulates central serotonergic pathways to further reduce nausea.

The specific dose and dosing schedule of Metoclopramida Labesfal are determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for Metoclopramida Labesfal in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and clinicians should consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Metoclopramida Labesfal differs from other antiemetics such as ondansetron by primarily acting as a dopamine D2 antagonist with additional 5‑HT3 antagonism. It is especially useful when both dopamine‑mediated and serotonergic pathways contribute to nausea, whereas drugs like ondansetron target only serotonin receptors.

Metoclopramida Labesfal should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability.

The product is supplied as an injectable solution for intramuscular or intravenous administration. Healthcare professionals should follow aseptic technique, dilute if required by the protocol, and administer the dose over the recommended time period.

Serious risks include the development of tardive dyskinesia, neuroleptic malignant syndrome, severe allergic reactions, and cardiac arrhythmias. Patients should be monitored for these events, especially during prolonged therapy or high‑dose regimens.

Metoclopramida Labesfal is contraindicated in individuals with known hypersensitivity to metoclopramide or any component of the formulation. Caution is advised for patients with Parkinson’s disease, seizure disorders, or a history of extrapyramidal reactions.